Moleculin: Moleculin Biotech begins dosing subjects in trial of combination therapy for AML

Moleculin Biotech has begun dosing subjects in a Phase III trial of Annamycin with Cytarabine for treating acute myeloid leukaemia (AML). The post Moleculin Biotech begins dosing subjects in trial of combination therapy for AML appeared first on Clinical Trials Arena.